Explore the cutting-edge advancements in chemical compound discovery with Zui Trieu, CTO of Nanyang Biologics, as he presents at the SuperAI Singapore 2025 Genesis Startup Competition. Nanyang Biologics, a pioneering spin-off from Nanyang Technological University, leverages AI technology to revolutionize drug discovery, offering a faster, safer, and more reliable alternative to traditional methods.

​

Their proprietary AI model, DTIGN, predicts how chemical compounds interact with the human body, significantly accelerating the identification of promising natural and synthetic compounds. By employing a sophisticated graph neural network, Nanyang Biologics reduces the time required for drug discovery from years to mere months, providing a cost-effective solution for both pharmaceuticals and consumer health sectors, which traditionally grapple with high testing costs and extended R&D timelines.

​

In this engaging talk, Zui Trieu reveals how AI is being utilized across industries including collaborations between giants like L'Oreal and Nvidia. He outlines Nanyang Biologics’ two-stage business model focused on natural compound opportunities and revenue generation through strategic partnerships with entities like Nvidia and Equinix. Highlighting a successful case study with Japanese Tobacco, the presentation showcases the AI-driven discovery of stress-reducing, non-addictive compounds.

​

Emphasizing the importance of AI in drug discovery and consumer health, Zui Trieu discusses the future roadmap and potential revenue streams for Nanyang Biologics, underlining their contributions to the global natural compound library. Don’t miss the opportunity to understand this revolutionary approach to drug discovery and its potential impacts on health and biotech industries.

​

If you find this insightful, please like, comment, and subscribe for more innovative talks and updates from leaders in science and technology.